Table 2.

Univariate Cox proportional hazard models for PFS in patients with non-small cell lung cancer harboring EGFR mutations who received ICI-based therapy

Items	Patient no	Univariate analysis
		Median PFS (95% CI)	p value
Age
< 70	18	2.5 (1.0–4.2)	0.77
≥ 70	18	2.6 (1.5–4.4)
Sex
Male	21	2.6 (1.1–4.2)	0.92
Female	15	2.4 (1.5–4.4)
ECOG-PS
0/1	27	3.7 (2.1–5.7)	0.0001
≥ 2	9	1.1 (0–2.6)
Stage
Postoperative recurrence	6	4.7 (1.2–NA)	0.27
III/IV	30	2.5 (1.5–4.0)
EGFR mutation
Common mutation	34	2.3 (1.5–3.7)	0.15
Uncommon mutation	2	5.5 (5.5–NA)
Smoking history
Current/former	13	2.4 (0.4–3.7)	0.46
Never	23	2.6 (1.6–5.5)
Regimen
Chemoimmunotherapy	18	4.9 (2.4–7.5)	0.003
ICI monotherapy	18	1.6 (1.1–2.1)
PD-L1 expression
≥ 50%	12	3.2 (0.2–7.5)	0.51
< 50%	21	2.1 (1.4–4.0)
p53 expression
Positive	19	4.0 (1.6–7.2)	0.04
Negative	17	2.1 (1.0–3.3)
AXL expression
High	7	2.1 (0.2–2.6)	0.65
Low	29	3.3 (1.6–4.4)

EGFR, epidermal growth factor receptor; ECOG-PS, Eastern Cooperative Oncology Group-performance status; ICI, immune checkpoint inhibitor; PD-L1 TPS, programmed death-ligand 1 tumor proportion score; PFS, progression-free survival; CI, confidence interval; NA, not available